Fornier Monica, Hudis Clifford
Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 457, New York, NY 10021, USA.
Curr Oncol Rep. 2005 Jan;7(1):18-22. doi: 10.1007/s11912-005-0021-1.
For patients with hormone-unresponsive or higher-risk operable early-stage breast cancer, adjuvant chemotherapy significantly reduces the risks of relapse and death. The prognosis for such patients, especially those presenting with extensive axillary lymph node involvement, remains poor. New chemotherapy agents and novel administration schedules have recently been shown to improve clinical outcome. This overview provides a summary of the state of the art and the most recent developments regarding adjuvant chemotherapy for primary breast carcinoma.
对于激素无反应或高风险可手术的早期乳腺癌患者，辅助化疗可显著降低复发和死亡风险。这类患者的预后仍然很差，尤其是那些伴有广泛腋窝淋巴结受累的患者。最近有研究表明，新型化疗药物和新颖的给药方案可改善临床结局。本综述总结了原发性乳腺癌辅助化疗的最新进展。
